Scan to Download ios&Android APP

Trade Royalty Pharma plc - RPRX CFD

44.22
0%
Market Trading Hours* (UTC) Open now
Closes on Wednesday at 20:00

Mon - Fri: 13:30 - 20:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading Conditions
Long position overnight fee -0.0225%
Short position overnight fee -0.0219%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 44.3
Open* 43.78
Day's Range* 43.7 - 43.7
1-Year Change* 13.27%
Volume N/A
Average Vol. (3m) 42.0861
52 wk Range N/A
Market Cap 26675.2
P/E Ratio 40.9249
Shares Outstanding 607220000
Revenue 2259.48
EPS 1.07343
Dividend (Yield %) 1.73003
Beta N/A
Next Earnings Date Nov 8, 2022

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Aug 16, 2022 44.30 0.74 1.70% 43.56 44.51 43.56
Aug 15, 2022 43.88 -0.10 -0.23% 43.98 44.26 43.65
Aug 12, 2022 44.14 0.50 1.15% 43.64 44.17 43.49
Aug 11, 2022 43.67 -0.10 -0.23% 43.77 44.08 43.46
Aug 10, 2022 43.87 0.43 0.99% 43.44 43.96 43.44
Aug 9, 2022 43.61 0.35 0.81% 43.26 43.90 43.09
Aug 8, 2022 43.07 0.56 1.32% 42.51 43.34 42.27
Aug 5, 2022 42.40 0.13 0.31% 42.27 43.51 42.25
Aug 4, 2022 42.46 0.07 0.17% 42.39 43.10 42.11
Aug 3, 2022 42.77 0.32 0.75% 42.45 42.95 42.45
Aug 2, 2022 42.38 -0.02 -0.05% 42.40 42.92 42.30
Aug 1, 2022 42.72 -0.62 -1.43% 43.34 43.39 42.59
Jul 29, 2022 43.42 0.63 1.47% 42.79 43.75 42.79
Jul 28, 2022 43.53 0.06 0.14% 43.47 43.95 42.78
Jul 27, 2022 43.60 1.19 2.81% 42.41 43.85 42.41
Jul 26, 2022 42.94 0.83 1.97% 42.11 43.33 42.11
Jul 25, 2022 42.89 -0.22 -0.51% 43.11 43.12 42.64
Jul 22, 2022 43.18 0.71 1.67% 42.47 43.38 42.40
Jul 21, 2022 42.70 -0.07 -0.16% 42.77 43.04 42.32
Jul 20, 2022 42.96 -0.53 -1.22% 43.49 43.71 42.77

Royalty Pharma plc Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2017 2018 2019 2020 2021
Total revenue 1597.93 1794.89 1814.25 2122.35 2289.46
Revenue 1597.93 1794.89 1814.25 2122.35 2289.46
Total Operating Expense 658.238 430.448 -808.922 557.454 858.748
Selling/General/Admin. Expenses, Total 106.44 61.906 103.439 181.715 182.826
Research & Development 117.866 392.609 83.036 26.289 200.084
Depreciation / Amortization 33.267 33.267 23.924 23.058 22.996
Other Operating Expenses, Total 400.665 -57.334 -1019.32 295.892 452.842
Operating Income 939.692 1364.45 2623.18 1564.9 1430.71
Interest Income (Expense), Net Non-Operating 352.353 154.927 -162.15 139.376 -183.836
Gain (Loss) on Sale of Assets 52.753 0 0
Other, Net -1.618 -1.518 0.393 -2.321 -5.678
Net Income Before Taxes 1343.18 1517.85 2461.42 1701.95 1241.2
Net Income After Taxes 1343.18 1517.85 2461.42 1701.95 1241.2
Minority Interest -133.155 -140.126 -112.884 -726.914 -621.473
Net Income Before Extra. Items 1210.03 1377.73 2348.53 975.04 619.728
Net Income 1210.03 1377.73 2348.53 975.04 619.728
Income Available to Common Excl. Extra. Items 1210.03 1377.73 2348.53 495.198 619.728
Income Available to Common Incl. Extra. Items 1210.03 1377.73 2348.53 495.198 619.728
Diluted Net Income 1210.03 1377.73 2348.53 495.198 619.728
Diluted Weighted Average Shares 595.383 595.383 595.383 375.455 414.802
Diluted EPS Excluding Extraordinary Items 2.03235 2.31402 3.94458 1.31893 1.49403
Dividends per Share - Common Stock Primary Issue 0 0 0 0.3 0.68
Diluted Normalized EPS 1.94374 2.31402 3.94458 1.57329 1.49403
Unusual Expense (Income) 30.5
Total Adjustments to Net Income -479.842
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total revenue 573.027 554.963 585.773 575.7 562.049
Revenue 573.027 554.963 585.773 575.7 562.049
Total Operating Expense 343.73 -189.986 282.721 422.283 342.331
Selling/General/Admin. Expenses, Total 43.156 44.921 48.588 46.161 51.54
Research & Development 2.641 3.122 90.5 103.821 100.5
Depreciation / Amortization 5.671 5.733 5.796 5.796 5.67
Other Operating Expenses, Total 292.262 -243.762 137.837 266.505 184.621
Operating Income 229.297 744.949 303.052 153.417 219.718
Interest Income (Expense), Net Non-Operating -70.361 61.913 -80.463 -94.926 -89.878
Other, Net 0.043 -0.107 -0.793 -4.82 -1.757
Net Income Before Taxes 158.979 806.755 221.796 53.671 128.083
Net Income After Taxes 158.979 806.755 221.796 53.671 128.083
Minority Interest -89.86 -365.979 -119.867 -45.767 -76.322
Net Income Before Extra. Items 69.119 440.776 101.929 7.904 51.761
Net Income 69.119 440.776 101.929 7.904 51.761
Income Available to Common Excl. Extra. Items 69.119 440.776 101.929 7.904 51.761
Income Available to Common Incl. Extra. Items 69.119 440.776 101.929 7.904 51.761
Diluted Net Income 69.119 440.776 101.929 7.904 51.761
Diluted Weighted Average Shares 607.148 607.163 607.174 431.417 607.201
Diluted EPS Excluding Extraordinary Items 0.11384 0.72596 0.16787 0.01832 0.08525
Dividends per Share - Common Stock Primary Issue 0.17 0.17 0.17 0.17 0.19
Diluted Normalized EPS 0.11384 0.72596 0.16787 0.01832 0.08525
  • Annual
  • Quarterly
2017 2018 2019 2020 2021
Total Current Assets 2608.55 832.072 2696.9 2878.21
Cash and Short Term Investments 2386.03 793.214 2649.14 2803.27
Cash & Equivalents 1924.21 283.682 1008.68 1541.05
Short Term Investments 461.821 509.532 1640.46 1262.22
Total Receivables, Net 198.627 38.766 39.166 68.309
Accounts Receivable - Trade, Net 35.996 33.525 33.155 53.286
Other Current Assets, Total 23.895 0.092 8.596 6.631
Total Assets 11370.1 12449.9 16020.3 17515.9
Intangibles, Net 75.648 51.724 28.666 5.67
Long Term Investments 8666.83 11478.1 13266.1 14627.8
Other Long Term Assets, Total 19.111 87.95 28.597 4.145
Total Current Liabilities 580.172 333.417 307.887 171.25
Payable/Accrued 4.477 11.177 10.775 5.62
Notes Payable/Short Term Debt 0 0 0 0
Current Port. of LT Debt/Capital Leases 281.436 281.984 0
Other Current Liabilities, Total 294.259 40.256 144.966 107.934
Total Liabilities 6881.93 6344.34 11201.5 11739.3
Total Long Term Debt 6237.9 5956.14 5816.58 7096.07
Long Term Debt 6237.9 5956.14 5816.58 7096.07
Minority Interest 63.865 35.883 5077.04 4471.95
Other Liabilities, Total 0 18.902 0
Total Equity 4488.21 6105.56 4818.78 5776.59
Common Stock 3282.52 3282.52 0.10222 0.10617
Retained Earnings (Accumulated Deficit) 1215.95 2825.21 1920.64 2255.18
Treasury Stock - Common 0 -4.266 -2.317 -2.715
Unrealized Gain (Loss) -10.255 2.093 34.395 16.491
Total Liabilities & Shareholders’ Equity 11370.1 12449.9 16020.3 17515.9
Total Common Shares Outstanding 595.383 595.383 607.111 607.176
Accrued Expenses 152.146 57.696
Additional Paid-In Capital 2865.96 3507.53
Other Equity, Total -0.00022 -0.00017
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total Current Assets 2416.02 2707.45 2775.76 2878.21 2982.42
Cash and Short Term Investments 2369.37 2650.52 2693.31 2803.27 2911.22
Cash & Equivalents 708.81 1142.28 1800.81 1541.05 1791.52
Short Term Investments 1660.56 1508.24 892.507 1262.22 1119.7
Total Receivables, Net 39.995 44.837 73.501 68.309 65.808
Accounts Receivable - Trade, Net 33.454 34.143 59.657 53.286 51.19
Other Current Assets, Total 6.657 12.098 8.945 6.631 5.388
Total Assets 15914.1 16514.9 17732.4 17515.9 17378.9
Intangibles, Net 22.995 17.262 11.466 5.67 0
Long Term Investments 13467.9 13784.2 14940.6 14627.8 14392.6
Other Long Term Assets, Total 7.14 5.96 4.515 4.145 3.87
Total Current Liabilities 255.983 283.989 255.055 171.25 135.871
Payable/Accrued 8.272 9.393 9.187 5.62 6.662
Accrued Expenses 120.271 152.904 126.733 57.696 13.199
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 127.44 121.692 119.135 107.934 116.01
Total Liabilities 11031.9 10781.2 11939.3 11739.3 11601.3
Total Long Term Debt 5821.07 5825.56 7090.67 7096.07 7101.14
Long Term Debt 5821.07 5825.56 7090.67 7096.07 7101.14
Minority Interest 4954.82 4671.69 4593.56 4471.95 4364.32
Total Equity 4882.21 5733.68 5793.07 5776.59 5777.56
Common Stock 0.10221 0.10518 0.10618 0.10617 0.10617
Additional Paid-In Capital 2931.25 3415.6 3454.22 3507.53 3543.2
Retained Earnings (Accumulated Deficit) 1923.77 2291.97 2320.88 2255.18 2224.68
Treasury Stock - Common -2.359 -2.662 -2.685 -2.715 -2.736
Other Equity, Total 29.4518 28.6718 20.5528 -0.00017 12.3038
Total Liabilities & Shareholders’ Equity 15914.1 16514.9 17732.4 17515.9 17378.9
Total Common Shares Outstanding 607.112 607.172 607.174 607.176 607.178
Unrealized Gain (Loss) 16.491
  • Annual
  • Quarterly
2017 2018 2019 2020 2021
Cash From Operating Activities 1418.31 1618.32 1667.24 2034.63 2017.54
Cash Receipts 1870.16 2287.91 2105.2 2329.23 2545.79
Cash Payments -74.681 -72.535 -88.524 -179.709 -184.511
Cash Interest Paid -235.205 -267.657 -254.964 -103.196 -130.43
Changes in Working Capital -141.961 -329.401 -94.471 -11.699 -213.318
Cash From Investing Activities -1587.71 303.424 -2116.14 -2759.32 -1870.28
Capital Expenditures -2290.71 -269.593 -1721.29 -2182.25 -2191.5
Other Investing Cash Flow Items, Total 703 573.017 -394.851 -577.074 321.222
Cash From Financing Activities -123.254 -1379.1 -1191.63 1487.17 385.112
Financing Cash Flow Items -1030.25 -1085.1 -897.626 -989.716 -602.237
Issuance (Retirement) of Debt, Net 907 -294 -294 680.634 1272.53
Net Change in Cash -292.648 542.64 -1640.53 762.481 532.368
Total Cash Dividends Paid -112.49 -285.184
Issuance (Retirement) of Stock, Net 1908.74 0
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Cash From Operating Activities 526.1 1057.82 1527.58 2017.54 460.27
Cash Receipts 616.528 1194.85 1908.41 2545.79 674.716
Cash Payments -42.16 -81.764 -135.272 -184.511 -48.902
Cash Interest Paid -64.5 -64.5 -129.759 -130.43 -86.216
Changes in Working Capital 16.232 9.232 -115.799 -213.318 -79.328
Cash From Investing Activities -599.3 -473.134 -1318.63 -1870.28 11.165
Capital Expenditures -503.07 -683.741 -2019.77 -2191.5 -0.085
Other Investing Cash Flow Items, Total -96.23 210.607 701.134 321.222 11.25
Cash From Financing Activities -226.67 -451.085 583.183 385.112 -220.966
Financing Cash Flow Items -160.687 -312.521 -477.769 -602.237 -138.703
Total Cash Dividends Paid -65.983 -138.564 -211.581 -285.184 -82.263
Issuance (Retirement) of Debt, Net 0 0 1272.53 1272.53
Net Change in Cash -299.87 133.601 792.128 532.368 250.469
Issuance (Retirement) of Stock, Net 0 0 0

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group
427000+

Traders

71000+

Active clients monthly

$46000000+

Monthly investing volume

$17000000+

Withdrawn each month

Royalty Pharma plc Company profile

About Royalty Pharma plc

Royalty Pharma plc is engaged in investing in late stage biopharmaceutical products. The Company invests in academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The Company’s portfolio of pharmaceutical investment includes investments in commercial products and development-stage product candidates. Its portfolio investments include AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko, Trikafta and OXLUMO.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Royalty Pharma plc revenues increased 8% to $2.29B. Net income applicable to common stockholders increased 25% to $619.7M. Revenues reflect Income from financial royalty assets increase of 5% to $2.07B, Other royalty income increase from $19M to $53.1M, Revenue from intangible royalty assets increase of 19% to $171.2M. Net income benefited from Other operating expenses decrease from $65.1M (expense) to $0K.

Industry: Pharmaceuticals (NEC)

110 East 59Th Street
10022

Income statement

People Also Watch

Bitcoin to US Dollar

23,394.45 Price
-2.410% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 21:00 (UTC)
Spread 60.00

Still looking for a broker you can trust?

Join the 427.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading